Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)
- Poster presentation
- Open Access
Adapting an immune competent mouse model for glioblastoma T cell therapy
Journal for ImmunoTherapy of Cancer volume 2, Article number: P35 (2014)
Glioblastoma (GBM) is the second most common, but most aggressive, primary brain tumor. Despite aggressive multimodal therapy consisting of surgery, radiation, and chemotherapy, the outcome of patients with GBM remains poor with 5-year survival rates of <10%. Therefore, new, targeted treatments are needed to improve outcomes, and adoptive T cell immunotherapy has the potential to fulfill this need. T cells genetically modified with chimeric antigen receptors (CARs) specific for cell surface antigens expressed in GBM such as HER2, EphA2, EGFRvIII, and IL13R (a1 and a2) have shown promising anti-GBM activity in preclinical GBM models. However, the majority of studies have been conducted in xenograft models that do not recapitulate the immunosuppressive tumor microenvironment. The goal of this project is now to adapt the established GL261 immune competent murine GBM model for the preclinical optimization of GBM-targeted CAR T cell therapies.
Since GL261 were readily killed by IL13R-specific human CAR T cells, we generated a retroviral vector encoding an IL13R-specific murine CAR with a CD28.CD3z endodomain. CD3-activated splenocytes were transduced with VSV-G pseudotyped retroviral particles, sorted, and used for functional in vitro studies. In contrast to non-transduced T cells, IL13R-specific murine CAR T cells recognize GL261, as judged by their ability to proliferate, secrete cytokines and kill GL261 cells in co-culture assays. IL13R-negative cells did not activate IL13R-specific murine CAR T cells, confirming antigen specificity. Animal experiments are in progress to evaluate the safety and efficacy of IL13R-specific murine CAR T cells in vivo.
In summary, our results indicate that is feasible to develop an immune competent murine GBM-targeted T cell immunotherapy model. Such a model will not only facilitate the translation of these therapies into the clinic, but will also allow us to realistically study how to best combine T cell therapy with other GBM-targeted therapies.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Rodriguez-Cruz, T., Yi, Z., Gottschalk, S. et al. Adapting an immune competent mouse model for glioblastoma T cell therapy. j. immunotherapy cancer 2 (Suppl 3), P35 (2014). https://doi.org/10.1186/2051-1426-2-S3-P35
- Cell Therapy
- Primary Brain Tumor
- Chimeric Antigen Receptor
- Multimodal Therapy
- Cell Surface Antigen